A phase I study of misonidazole and pelvic irradiation in patients with carcinoma of cervix.

A Phase I study of oral daily misonidazole (MISO) with conventional pelvic irradiation, has been conducted in patients with carcinoma of the cervix Stages IB, IIB, IIIB and IVA. MISO was administered in daily dosages to sequential groups of patients at doses of 0.15 g/m2, 0.30 g/m2 or 0.45 g/m2 for...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, G. M., Rauth, A. M., Black, B. E., Cummings, B. J., Sorenti, V. L., Bush, R. S.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1982
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011033/
https://www.ncbi.nlm.nih.gov/pubmed/6284190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011033/
https://www.ncbi.nlm.nih.gov/pubmed/6284190

Ejemplares similares